STAGE III PANCREATIC CANCER AJCC V6 AND V7
Clinical trials for STAGE III PANCREATIC CANCER AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE III PANCREATIC CANCER AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE III PANCREATIC CANCER AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine approach targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis early-phase study tested a vaccine therapy given directly into the tumor along with a growth factor to boost the immune system in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effe…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Could a diabetes drug and supplements boost chemo for pancreatic cancer?
Disease control OngoingThis early-phase study tests whether adding the diabetes drug metformin and a specific dietary supplement mix to standard chemotherapy is safe and feasible for people with pancreatic cancer that cannot be removed by surgery. The supplement includes ingredients like curcumin, vita…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug combo targets tough cancers: hope for liver, pancreas, and bile duct tumors
Disease control OngoingThis early-phase study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The main goals are to find the safest dose and see if the drugs can shrink tumors. About 55 particip…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New drug cocktail targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 patients with advanced pancreatic cancer that had spread or could not be removed by surgery. The main goal was to find the safest dose and check for side effects. Researchers …
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New drug combo aims to boost Radiation's punch against tough GI cancers
Symptom relief OngoingThis early-phase study tested an oral drug called ropidoxuridine (IPdR) in 19 people with advanced gastrointestinal cancers that could not be cured. The goal was to find the safest dose and see if the drug could make tumor cells more sensitive to radiation therapy. The study focu…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated May 17, 2026 05:34 UTC